Karyopharm Therapeutics
KPTI
KPTI
171 hedge funds and large institutions have $637M invested in Karyopharm Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
34% less call options, than puts
Call options by funds: $2.61M | Put options by funds: $3.95M
36% less capital invested
Capital invested by funds: $987M → $637M (-$351M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
171
Holding in Top 10
1
Calls
$2.61M
Puts
$3.95M
Top Buyers
| 1 | +$15.3M | |
| 2 | +$11.2M | |
| 3 | +$10.1M | |
| 4 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$8.73M |
| 5 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$8.73M |
Top Sellers
| 1 | -$20.1M | |
| 2 | -$18.7M | |
| 3 | -$18.5M | |
| 4 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$17.3M |
| 5 |
D.E. Shaw & Co
New York
|
-$14.3M |